Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma. 1999

H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
Department of Internal Medicine, Sapporo Medical University, Japan.

BACKGROUND The prognosis of patients with hepatocellular carcinoma is relatively poor because of the high rate of intrahepatic recurrences. We have previously demonstrated an association between enhanced secretion of active matrix metalloproteinases (MMPs; gelatinase A and matrilysin) and early recurrence in hepatocellular carcinoma. The aim of this study was to examine further the relationship between messenger RNA levels of metalloproteinases and their inhibitors and behavior of this carcinoma. METHODS Messenger RNA expression of gelatinase A, gelatinase B, matrilysin and tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 were analyzed in 30 patients with hepatocellular carcinoma by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). The results were contrasted with the clinicopathological data of the patients. RESULTS Enhanced mRNA expression of gelatinase A, gelatinase B and matrilysin in tumor was observed in 20, 22 and 19 of 30 patients, respectively. Enhanced mRNA expression of gelatinase A or gelatinase B and of matrilysin showed trends toward presence of capsular invasion (P = 0.078) and intrahepatic metastasis (P = 0.064), respectively. Concomitant overexpression of gelatinase A and matrilysin was associated with portal invasion, intrahepatic metastasis and recurrence within the first postoperative year (P < 0.05). A modest increase of mRNA expression of TIMP-1 and TIMP-2 in tumor was observed in half of the patients, but did not correlate with any clinicopathological features. CONCLUSIONS Our results suggest that semiquantitative RT-PCR analysis of MMPs may be helpful in disease management of patients with hepatocellular carcinoma.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D017364 Collagenases Enzymes that catalyze the degradation of collagen by acting on the peptide bonds. Collagen Peptidase,Collagen-Degrading Enzyme,Collagenase,Collagen Degrading Enzyme,Peptidase, Collagen
D020133 Reverse Transcriptase Polymerase Chain Reaction A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols. Polymerase Chain Reaction, Reverse Transcriptase,Reverse Transcriptase PCR,PCR, Reverse Transcriptase,Transcriptase PCR, Reverse
D020780 Matrix Metalloproteinase 9 An endopeptidase that is structurally similar to MATRIX METALLOPROTEINASE 2. It degrades GELATIN types I and V; COLLAGEN TYPE IV; and COLLAGEN TYPE V. Gelatinase B,92-kDa Gelatinase,92-kDa Type IV Collagenase,MMP-9 Metalloproteinase,MMP9 Metalloproteinase,Matrix Metalloproteinase-9,92 kDa Gelatinase,92 kDa Type IV Collagenase,MMP 9 Metalloproteinase,Metalloproteinase 9, Matrix,Metalloproteinase, MMP-9,Metalloproteinase, MMP9

Related Publications

H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
June 2003, Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University,
H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
March 2001, Bone,
H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
April 2001, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
July 1997, The Journal of pathology,
H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
December 2000, The Korean journal of internal medicine,
H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
January 2013, World journal of surgical oncology,
H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
September 2003, Biology of reproduction,
H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
August 1995, Journal of neurosurgery,
H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
October 2005, Histopathology,
H Yamamoto, and F Itoh, and Y Adachi, and H Fukushima, and H Itoh, and S Sasaki, and Y Hinoda, and K Imai
January 2007, Surgical neurology,
Copied contents to your clipboard!